Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States - PubMed (original) (raw)
. 2012 May;19(5):1685-91.
doi: 10.1245/s10434-011-2141-1. Epub 2011 Dec 1.
Affiliations
- PMID: 22130619
- DOI: 10.1245/s10434-011-2141-1
Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States
Putao Cen et al. Ann Surg Oncol. 2012 May.
Abstract
Background: Our aim was to evaluate the changes in age, stage distribution, and overall survival (OS) of patients with esophageal adenocarcinoma (EAC) over time.
Methods: Patients from the Surveillance, Epidemiology, and End Results (SEER) database aged ≥ 20 with invasive EAC, diagnosed from 1973-2003 were reviewed. Survival follow-up ended in 2006.
Results: There were 11,620 patients; 6580 (57%) aged ≥ 65. The stage distribution was 22%, 35%, and 43% for localized, regional, and distant metastasis for patients aged <65, and 33%, 33%, and 34% for patients aged ≥ 65. The number of patients ≥ 65 years with localized stage increased over time. Three-year OS for localized, regional, and distant disease increased from 19%, 10%, and 1% in 1973-1976, to 34%, 13%, and 2% in 1987-1991, and to 45%, 25%, and 4% in 2002-2003 (P < 0.001). A sub-analysis of 5475 patients from 1988-2002 showed better survival for patients with esophagectomy for all stages. Three-year OS for 2074 patients with esophagectomy improved every 5 years from 1988-2002 (39%, 43% to 54%, P < 0.001). Stratified by stage, year and esophagectomy status, patients aged <65 had better survival compared to patients aged ≥ 65 (P < 0.001).
Conclusions: There has been a substantial improvement in overall survival among patients with invasive EAC over the last 3 decades. Patients receiving esophagectomy had longer survival. Survival with esophagectomy improved in each time period. Although younger EAC patients were diagnosed at more advanced stages over time, they had better survival.
Similar articles
- Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?
Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB. Eloubeidi MA, et al. Am J Gastroenterol. 2003 Jul;98(7):1627-33. doi: 10.1111/j.1572-0241.2003.07454.x. Am J Gastroenterol. 2003. PMID: 12873590 - En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
Rizzetto C, DeMeester SR, Hagen JA, Peyre CG, Lipham JC, DeMeester TR. Rizzetto C, et al. J Thorac Cardiovasc Surg. 2008 Jun;135(6):1228-36. doi: 10.1016/j.jtcvs.2007.10.082. Epub 2008 May 23. J Thorac Cardiovasc Surg. 2008. PMID: 18544359 - Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Liao Z, et al. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1484-93. doi: 10.1016/j.ijrobp.2004.05.056. Int J Radiat Oncol Biol Phys. 2004. PMID: 15590179 - Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study.
Schwer AL, Ballonoff A, McCammon R, Rusthoven K, D'Agostino RB Jr, Schefter TE. Schwer AL, et al. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):449-55. doi: 10.1016/j.ijrobp.2008.04.022. Epub 2008 Jun 4. Int J Radiat Oncol Biol Phys. 2009. PMID: 18538500 - Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Mariette C, et al. Ann Thorac Surg. 2004 Oct;78(4):1177-83. doi: 10.1016/j.athoracsur.2004.02.068. Ann Thorac Surg. 2004. PMID: 15464466 Review.
Cited by
- MicroRNA Expression can be a Promising Strategy for the Detection of Barrett's Esophagus: A Pilot Study.
Bansal A, Hong X, Lee IH, Krishnadath KK, Mathur SC, Gunewardena S, Rastogi A, Sharma P, Christenson LK. Bansal A, et al. Clin Transl Gastroenterol. 2014 Dec 11;5(12):e65. doi: 10.1038/ctg.2014.17. Clin Transl Gastroenterol. 2014. PMID: 25502391 Free PMC article. - Overexpression of CTEN relates to tumor malignant potential and poor outcomes of adenocarcinoma of the esophagogastric junction.
Aratani K, Komatsu S, Ichikawa D, Ohashi T, Miyamae M, Okajima W, Imamura T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E. Aratani K, et al. Oncotarget. 2017 Sep 20;8(48):84112-84122. doi: 10.18632/oncotarget.21109. eCollection 2017 Oct 13. Oncotarget. 2017. PMID: 29137409 Free PMC article. - Cancer-associated fibroblast-derived CXCL12 causes tumor progression in adenocarcinoma of the esophagogastric junction.
Sugihara H, Ishimoto T, Yasuda T, Izumi D, Eto K, Sawayama H, Miyake K, Kurashige J, Imamura Y, Hiyoshi Y, Iwatsuki M, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, Yoshida N, Watanabe M, Takamori H, Baba H. Sugihara H, et al. Med Oncol. 2015 Jun;32(6):618. doi: 10.1007/s12032-015-0618-7. Epub 2015 Apr 24. Med Oncol. 2015. PMID: 25920609 - Overexpression of YWHAZ as an independent prognostic factor in adenocarcinoma of the esophago-gastric junction.
Watanabe N, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Okajima W, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E. Watanabe N, et al. Am J Cancer Res. 2016 Nov 1;6(11):2729-2736. eCollection 2016. Am J Cancer Res. 2016. PMID: 27904785 Free PMC article. - Retrospective study using the propensity score to clarify the oncologic feasibility of thoracoscopic esophagectomy in patients with esophageal cancer.
Takeno S, Takahashi Y, Moroga T, Kawahara K, Yamashita Y, Ohtaki M. Takeno S, et al. World J Surg. 2013 Jul;37(7):1673-80. doi: 10.1007/s00268-013-2008-7. World J Surg. 2013. PMID: 23539192
MeSH terms
LinkOut - more resources
Full Text Sources
Medical